Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis

Clinical Therapeutics

Volumn 35, Issue 8, 2013, Pages 1137-1149

  Wisniacki, Nicolas ^a   Amaravadi, Lakshmi ^b   Galluppi, Gerald R ^a   Zheng, Timothy S ^b   Zhang, Ray ^b   Kong, Jessica ^b   Burkly, Linda C ^b  

^a Medical Research   (United Kingdom)

^b BIOGEN   (United States)

Author keywords

Fn14; Pharmacodynamics; Pharmacokinetics; TWEAK

Indexed keywords

BIIB 023; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; RHEUMATOID ARTHRITIS;

FN14; PHARMACODYNAMICS; PHARMACOKINETICS; TWEAK;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS; YOUNG ADULT;

EID: 84882854274     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.008     Document Type: Article

References (22)

1. Burkly L.C., Michaelson J.S., Zheng T.S. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011, 244:99-114.
2. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
3. Burkly L.C., Michaelson J.S., Hahm K., et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathways in health and disease. Cytokine 2007, 40:1-16.
4. Zheng T.S., Burkly L.C. No end in site: TWEAK/Fn14 activation and autoimmunity associated-end-organ pathologies. J Leukocyte Biol 2008, 84:338-347.
5. Burkly L.C., Dohi T. The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol 2011, 691:305-322.
6. Schwartz N., Rubinstein T., Burkly L.C., et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009, 11:R143.
7. Schwartz N., Su L., Burkly L.C., et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmunol 2006, 27:242-250.
8. Harada N., Nakayama M., Nkano H., et al. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002, 299:488-493.
9. Saitoh T., Nakayama M., Nakano H., et al. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003, 278:36005-36012.
10. Chicheportiche Y., Bourdon P.R., Xu H., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-32410.
11. Justo P., Sanz A.B., Sanchez-Nino M.D., et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006, 70:1750-1758.
12. Kamata K., Kmaijo S., Nakajima A., et al. Involvement of TNF-like WEAK inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006, 177:6433-6439.
13. Perper S.J., Browning B., Burkly L.C., et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006, 177:2610-2620.
14. Michaelson J.S., Wiskniacki N., Burkly L.C., Putterman C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmune 2012, 39:130-142.
15. Dohi T., Borodovsky A., Wu P., et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 2009, 136:912-923.
16. Zhao Z., Burkly L.C., Campbell S., et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007, 179:7949-7958.
17. Kaine J., Gladstein G., Strusberg I., et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study). Ann Rheum Dis 2012, 71:38-44.
18. Haringman J.J., Gerlag D.M., Smeets T.J., et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2387-2392.
19. Bauer J.W., Petri M., Batliwalla F.M., et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60:3098-3107.
20. Horstrup J.H., Gehrmann M., Schneider B., et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 2002, 17:1005-1013.
21. Cai G., Zhang X., Hong Q., et al. Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol Dial Transplant 2008, 23:1861-1875.
22. ATLAS - Anti-Tweak in Lupus Nephritis Patients. ClinicalTrials.gov. Last updated February 16, 2012. Accessed March 22, 2012. http://clinicaltrials.gov/ct2/show/NCT01499355?term=BIIB023&rank=3.